Oncofocus
  • Services
    • Primary Market Research
    • Competitive Intelligence
  • About
  • Blog
  • Reports
  • Careers
  • Contact
“So it is said that if you know your enemies and know yourself, you can win a hundred battles without a single loss.
​If you only know yourself, but not your opponent, you may win or may lose.
​If you know
neither yourself nor your enemy, you will always endanger yourself.”
​- Sun Tzu from Art of War

Small Cell Lung Cancer Indication

18/9/2019

0 Comments

 

Immune Checkpoint Inhibitors (ICIs) Pipeline Landscape

SCLC is an unforgiving, highly aggressive variant of lung cancer. It accounts for approximately 15% of the lung cancer cases globally and is also a major cause of cancer-related deaths. ​The chemotherapy has been the mainstay in SCLC management. While response rate to chemotherapy is high, notably, almost all patients relapse after few months (PFS is typically 4.0 - 5.5 months).
Picture
Read More
0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    Categories

    All
    BCMA
    CARTs
    Cervical Cancer
    Melanoma
    Multiple Myeloma
    PD-1 And PD-L1
    Pipeline Landscape

    Archives

    November 2019
    October 2019
    September 2019
    April 2019
    August 2017

Bangalore Office
Oncofocus Solutions Pvt Ltd, 

#4, II Floor, 5th Main, 9th Cross, Jaya Mahal Ext,
Bengaluru
, India 56 00 46

Tel. +91 89044 00482

E-mail: support@oncofocus.com
RFQ: rfq@oncofocus.com
​

Singapore Office (Sales)
Oncofocus Solutions Pte Ltd, 

51 Goldhill Plaza, 
#07-10/11
​Singapore 30 89 00
​



E-mail: support@oncofocus.com.sg
​RFQ: rfq@oncofocus.com
​

    Subscribe to our Newsletter

Subscribe to Newsletter
Tweets by oncofocus
  • Services
    • Primary Market Research
    • Competitive Intelligence
  • About
  • Blog
  • Reports
  • Careers
  • Contact